Bempikibart (ADX-914) is under development for the treatment of atopic dermatitis and alopecia areata. It is administered through subcutaneous route and acts by targeting interleukin-7 receptor (IL-7R ...

SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 ...

The biotech—which went public earlier this year via a merger with Homology Medicines—had been evaluating bempikibart in a phase 2b study of 106 patients with moderate to severe atopic dermatitis.

Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which identified encouraging clinical activity in patients ...

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of its lead candidate, bempikibart (ADX-914). The clinical-stage biotech ...

WALTHAM, Mass. - Q32 Bio Inc. (NASDAQ: QTTB), a biotechnology firm specializing in immune system therapeutics, has announced plans to progress its drug candidate bempikibart after observing ...

Piper Sandler analyst Christopher Raymond lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $85 and keeps an Overweight rating on ...

Shares of Q32 Bio QTTB lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies evaluating its investigational drug bempikibart one in atopic dermatitis (AD or ...